Johnson & Johnson decided to terminate a $1.6 billion partnership with Argenx to develop the anti-CD70 antibody cusatuzumab to treat amyotrophic lateral sclerosis (AML) and myelodysplastic syndromes (MDS).
https://www.pharmalive.com/wp-content/uploads/2021/06/Argenx-Regains-Rights-to-Blood-Cancer-Drug-Following-Dropped-1.6-Billion-Deal-BioSpace-6-8-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-06-08 10:24:362021-06-08 10:28:51Argenx Regains Rights to Blood Cancer Drug from J&J